EUVIMEDEUVIMED entdecken
Fallbericht

Differential diagnosis in immune checkpoint inhibitors neurotoxicity

Catherine R Garcia, Ian J Robertson, Timothy A Gregory, Anza Zahid, Behrang Amini, Carlos Kamiya-Matsuoka, Sudhakar Tummala

Journal of Neurology · 2025

DOI: 10.1007/s00415-024-12872-6 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Neurology, 2025. Verfasst von Catherine R Garcia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. cgarcia18@mdanderson.org. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neurotoxicity Syndromes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neurologic symptoms seen in patients receiving immune checkpoint inhibitors (ICI) may not be entirely caused by immunotoxicity. We aim to highlight these confounding conditions through clinical cases to encourage early recognition and management. METHODS: We describe a series of seven cases from our institution that were treated with ICI and presented with Neurologic symptoms and were diagnosed with superimposed conditions beyond immunotoxicity. RESULTS: A total of 7 cases are described that include acute motor axonal neuropathy with vitamin B12 deficiency, lumbosacral radiculopathy with Wernicke's, Herpes simplex virus (HSV) encephalitis reactivation, central nervous system vasculitis with renal vasculitis, myositis with fasciitis, myositis with fixed clinical deficit at resolution, and synovitis with accompanying carpal tunnel syndrome. Primary cancer site included lung adenocarcinoma (2/7), melanoma (4/7), and oropharyngeal squamous cell carcinoma (1/7). All patients had received treatment with more than one ICI. Median number of cycles prior to neurotoxicity was 3 cycles. DISCUSSION: Neurologic symptoms seen in patients receiving ICI may include other causes beyond immunotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeurotoxicity SyndromesHumansMaleFemaleMiddle AgedAgedDiagnosis, DifferentialAged, 80 and over

Stichwörter der Autor:innen

Adverse eventImmune checkpoint inhibitorImmunotherapyNeurotoxicity

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. cgarcia18@mdanderson.org.
  • Department of Internal Medicine, Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Department of Neurology, Madigan Army Medical Center, Tacoma, WA, USA.
  • Department of Neurology, Houston Methodist Hospital, Houston, TX, USA.
  • Department of Musculoskeletal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Zitieren

APA

Garcia, C. R., Robertson, I. J., Gregory, T. A., Zahid, A., Amini, B., Kamiya-Matsuoka, C., & Tummala, S. (2025). Differential diagnosis in immune checkpoint inhibitors neurotoxicity. Journal of Neurology. https://doi.org/10.1007/s00415-024-12872-6

Vancouver

Garcia CR, Robertson IJ, Gregory TA, Zahid A, Amini B, Kamiya-Matsuoka C, et al. Differential diagnosis in immune checkpoint inhibitors neurotoxicity. Journal of Neurology. 2025. doi:10.1007/s00415-024-12872-6

BibTeX
@article{Garcia2025,
  author = {Garcia, Catherine R and Robertson, Ian J and Gregory, Timothy A and Zahid, Anza and Amini, Behrang and Kamiya-Matsuoka, Carlos and Tummala, Sudhakar},
  title = {Differential diagnosis in immune checkpoint inhibitors neurotoxicity},
  journal = {Journal of Neurology},
  year = {2025},
  doi = {10.1007/s00415-024-12872-6}
}
Kostenlos starten →